ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: PO0878

Association of Different Definitions of Intradialytic Hypertension with Long-Term Mortality in Hemodialysis

Session Information

Category: Dialysis

  • 701 Dialysis: Hemodialysis and Frequent Dialysis


  • Singh, Anika T., Brigham and Women's Hospital, Boston, Massachusetts, United States
  • Waikar, Sushrut S., Boston Medical Center, Boston, Massachusetts, United States
  • McCausland, Finnian R., Brigham and Women's Hospital, Boston, Massachusetts, United States

Hypertension is common in patients receiving maintenance hemodialysis (HD). A subset of patients experience increases in systolic blood pressure (SBP) from pre- to post-HD (intradialytic hypertension). This phenomenon is known to be associated with adverse short and long-term outcomes, but there is little consensus on an evidence-based definition.


In a retrospective cohort of 3,198 HD participants, unadjusted and adjusted Cox proportional hazards models were fit to examine the association of various definitions of intradialytic hypertension (≥30% of baseline sessions with an increase in pre- to post-HD SBP of 1) ≥0 mmHg [Hyper0]; 2) ≥10 mmHg [Hyper10], or 3) ≥20 mmHg increase [Hyper20]) with all-cause mortality. Interaction terms were used to assess for effect modification according to pre-specified demographic (age, sex), HD-related (pre-HD SBP, ultrafiltration rate), and comorbid disease variables (diabetes, heart failure, and peripheral vascular disease [PVD]).


At baseline, mean age was 62 ±15 years, 57% were male, and 14% were Black. Average change in BP from pre- to post-HD was 13 ±16 mmHg (median 12 [3 to 22] mmHg). During the baseline period, 47% of individuals met the Hyper0 definition and were at a 29% (HR 1.29; 95%CI 1.03 to 1.62) higher adjusted risk of death, compared with participants with no SBP increase. Hyper10 was present in 21.2% and associated with a 21% higher adjusted risk of death (HR 1.21; 95%CI 0.96 to 1.51). Hyper20 was present in 6.8% and associated with a 5% higher risk of death (HR 1.05; 95%CI 0.76 to 1.46). There was evidence for effect modification by age and PVD (P-interaction=0.02 for both), with a higher risk of death in those aged 45-70 years and those without PVD.


Individuals with any increase in SBP from pre- to post-HD experienced the highest adjusted risk of mortality, compared with other threshold-based definitions with effect modification by age and PVD.


  • NIDDK Support